KRAS and cancer: If successful, these KRAS mutation-selective inhibitors and pan-KRAS inhibitors and degraders will move beyond selective inhibitors of KRASG12C and provide novel therapeutics for not only PDAC patients but also all other patients with KRAS-driven cancers such as NSCLCs and CRCs.